MYCN and neuroblastoma: As neuroblastoma displays substantial genetic heterogeneity, most prominently heterogeneous amplification of the oncogenic driver MYCN [5,100], and since FAIM2 expression was associated with MYCN-amplification status in tumors, but not DTCs, it will be important to evaluate the correlation of genetic and phenotypic heterogeneity.